

Supplementary Materials for  
Consolidated Financial Results  
for the 2nd Quarter of Fiscal Year 2011. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Extraordinary Gains and Losses, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

Fx rates											Revised Forecast (released on July 21)
	FY2008	FY2009	FY2010				FY2011				FY2011
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	7-12
	(Full-year)	(Full-year)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(2nd Half)
	average	average	average	average	average	average	average	average	average	average	forecast
CHF	95.54	86.20	85.80	84.42	84.00	84.17	87.30	90.38	–	–	95.00
EUR	151.38	130.10	125.58	121.21	117.66	116.32	112.36	114.86	–	–	110.00
USD	103.44	93.60	90.69	91.41	89.56	87.81	82.23	81.93	–	–	85.00
GBP	189.85	145.99	141.62	139.45	137.32	135.65	131.71	132.43	–	–	131.00

## Financial Highlights (YTD)

(Billions of Yen)

																Revised Forecast (released on July 21)			
		FY2008	FY2009	FY2010				FY2011								FY2011			
		1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
		Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year(Actual)		Full-year	
Revenues		326.9	428.9	87.1	182.4	276.1	379.5	85.7	(1.6)	181.9	(0.3)	—	—	—	—	181.9	(0.3)	395.2	+4.1
	Sales	321.8	419.1	86.2	180.6	273.3	375.6	80.4	(6.7)	174.8	(3.2)	—	—	—	—	174.8	(3.2)	384.5	+2.4
	excl. Tamiflu	313.4	342.9	75.4	168.6	257.4	357.4	76.2	+1.1	170.2	+0.9	—	—	—	—	170.2	+0.9	374.3	+4.7
	Tamiflu	8.4	76.2	10.8	12.0	15.8	18.2	4.2	(61.1)	4.6	(61.7)	—	—	—	—	4.6	(61.7)	10.2	(44.0)
	Ordinary sales	7.1	36.2	1.4	1.4	1.4	1.6	3.7	+164.3	4.1	+192.9	—	—	—	—	4.1	+192.9	6.7	+318.8
	Govt. stockpile etc.	1.3	40.0	9.5	10.6	14.4	16.6	0.5	(94.7)	0.5	(95.3)	—	—	—	—	0.5	(95.3)	3.5	(78.9)
	Other operating revenues	5.1	9.8	0.9	1.7	2.8	3.9	5.3	+488.9	7.2	+323.5	—	—	—	—	7.2	+323.5	10.7	+174.4
Cost of sales		127.0	192.9	41.1	80.5	119.6	162.4	35.1	(14.6)	74.5	(7.5)	—	—	—	—	74.5	(7.5)	167.2	+3.0
(% of Sales)		39.5	46.0	47.7	44.6	43.8	43.2	43.7	—	42.6	—	—	—	—	—	42.6	—	43.5	—
Gross profit		199.9	236.1	46.0	101.8	156.5	217.1	50.6	+10.0	107.4	+5.5	—	—	—	—	107.4	+5.5	228.0	+5.0
(% of Revenues)		61.2	55.0	52.8	55.8	56.7	57.2	59.0	—	59.0	—	—	—	—	—	59.0	—	57.7	—
SG&A (excl. R&D) expenses		95.1	98.2	22.8	47.7	71.4	96.2	22.0	(3.5)	45.3	(5.0)	—	—	—	—	45.3	(5.0)	98.0	+1.9
(% of Revenues)		29.1	22.9	26.2	26.2	25.9	25.3	25.7	—	24.9	—	—	—	—	—	24.9	—	24.8	—
R&D expenses		53.2	55.3	12.2	26.6	39.9	54.7	13.0	+6.6	26.9	+1.1	—	—	—	—	26.9	+1.1	58.0	+6.0
(% of Revenues)		16.3	12.9	14.0	14.6	14.5	14.4	15.2	—	14.8	—	—	—	—	—	14.8	—	14.7	—
Operating income		51.6	82.6	11.1	27.6	45.1	66.2	15.6	+40.5	35.2	+27.5	—	—	—	—	35.2	+27.5	72.0	+8.8
(% of Revenues)		15.8	19.3	12.7	15.1	16.3	17.4	18.2	—	19.4	—	—	—	—	—	19.4	—	18.2	—
Non-operating income		9.9	9.4	1.3	3.0	2.2	2.4	2.1	+61.5	1.3	(56.7)	—	—	—	—	1.3	(56.7)	—	—
Non-operating expenses		4.2	1.6	0.3	4.4	3.0	3.5	1.0	+233.3	0.4	(90.9)	—	—	—	—	0.4	(90.9)	—	—
Ordinary income		57.3	90.4	12.1	26.2	44.3	65.1	16.7	+38.0	36.2	+38.2	—	—	—	—	36.2	+38.2	73.1	+12.3
(% of Revenues)		17.5	21.1	13.9	14.4	16.0	17.2	19.5	—	19.9	—	—	—	—	—	19.9	—	18.5	—
Extraordinary gain		7.3	0.3	0.1	0.1	0.1	0.6	—	(100.0)	—	(100.0)	—	—	—	—	—	(100.0)	—	—
Extraordinary loss		1.4	1.3	0.0	0.1	0.1	0.0	7.1	—	7.6	+7,500.0	—	—	—	—	7.6	+7,500.0	—	—
Income before income taxes etc.		63.1	89.4	12.1	26.1	44.3	65.7	9.6	(20.7)	28.6	+9.6	—	—	—	—	28.6	+9.6	—	—
(% of Revenues)		19.3	20.8	13.9	14.3	16.0	17.3	11.2	—	15.7	—	—	—	—	—	15.7	—	—	—
Net income		39.3	56.6	7.9	16.4	28.1	41.4	5.0	(36.7)	17.1	+4.3	—	—	—	—	17.1	+4.3	37.0	(10.6)
(% of Revenues)		12.0	13.2	9.1	9.0	10.2	10.9	5.8	—	9.4	—	—	—	—	—	9.4	—	9.4	—

## Extraordinary Gains and Losses

## Extraordinary Losses

(Billions of Yen)

	Amount	Description
Loss on disaster	6.5	<ul style="list-style-type: none"> <li>• Expenses due to impact of the Great East Japan Earthquake, offsetting with estimated insurance proceeds.</li> <li>• Most of the damage were incurred at Utsunomiya Plant. The following are included in the amount. <ul style="list-style-type: none"> <li>— loss on and restoration costs for damaged PP&amp;E</li> <li>— demolition costs for damaged assets</li> <li>— loss on inventories</li> <li>— fixed costs during shutdown, etc.</li> </ul> </li> </ul>
Loss on adjustment for changes of accounting standard for asset retirement obligations	1.0	The impact at beginning of the year due to application of “Accounting Standards for Asset Retirement Obligations”

(Billions of Yen)

																Revised Forecast (released on July 21)			
		FY2008	FY2009	FY2010				FY2011								FY2011			
		1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	Change (%)	7-12	Change (%)
		Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1st Half(Actual)		2nd Half	
Revenues		326.9	428.9	87.1	95.3	93.7	103.4	85.7	(1.6)	96.2	+0.9	-	-	-	-	181.9	(0.3)	213.3	+8.2
Sales		321.8	419.1	86.2	94.5	92.6	102.3	80.4	(6.7)	94.4	(0.1)	-	-	-	-	174.8	(3.2)	209.7	+7.6
excl. Tamiflu		313.4	342.9	75.4	93.3	88.8	100.0	76.2	+1.1	94.0	+0.8	-	-	-	-	170.2	+0.9	204.2	+8.2
Tamiflu		8.4	76.2	10.8	1.2	3.8	2.3	4.2	(61.1)	0.4	(66.7)	-	-	-	-	4.6	(61.7)	5.6	(8.2)
Ordinary sales		7.1	36.2	1.4	0.0	0.0	0.2	3.7	+164.3	0.4	-	-	-	-	-	4.1	+192.9	2.6	+1,200.0
Govt. stockpile etc.		1.3	40.0	9.5	1.2	3.8	2.1	0.5	(94.7)	-	(100.0)	-	-	-	-	0.5	(95.3)	3.0	(49.2)
Other operating revenues		5.1	9.8	0.9	0.8	1.1	1.1	5.3	+488.9	1.8	+125.0	-	-	-	-	7.2	+323.5	3.5	+59.1
Cost of sales		127.0	192.9	41.1	39.5	39.1	42.8	35.1	(14.6)	39.4	(0.3)	-	-	-	-	74.5	(7.5)	92.7	+13.2
(% of Sales)		39.5	46.0	47.7	41.8	42.2	41.8	43.7	-	41.7	-	-	-	-	-	42.6	-	44.2	-
Gross profit		199.9	236.1	46.0	55.8	54.6	60.6	50.6	+10.0	56.8	+1.8	-	-	-	-	107.4	+5.5	120.6	+4.6
(% of Revenues)		61.2	55.0	52.8	58.6	58.3	58.6	59.0	-	59.0	-	-	-	-	-	59.0	-	56.5	-
SG&A (excl. R&D) expenses		95.1	98.2	22.8	24.9	23.7	24.7	22.0	(3.5)	23.2	(6.8)	-	-	-	-	45.3	(5.0)	52.7	+8.9
(% of Revenues)		29.1	22.9	26.2	26.1	25.3	23.9	25.7	-	24.1	-	-	-	-	-	24.9	-	24.7	-
R&D expenses		53.2	55.3	12.2	14.4	13.3	14.8	13.0	+6.6	13.9	(3.5)	-	-	-	-	26.9	+1.1	31.1	+10.7
(% of Revenues)		16.3	12.9	14.0	15.1	14.2	14.3	15.2	-	14.4	-	-	-	-	-	14.8	-	14.6	-
Operating income		51.6	82.6	11.1	16.5	17.6	21.1	15.6	+40.5	19.6	+18.8	-	-	-	-	35.2	+27.5	36.8	(4.9)
(% of Revenues)		15.8	19.3	12.7	17.3	18.8	20.4	18.2	-	20.4	-	-	-	-	-	19.4	-	17.3	-
Non-operating income		9.9	9.4	1.3	1.7	1.6	0.5	2.1	+61.5	1.2	(29.4)	-	-	-	-	1.3	(56.7)	-	-
Non-operating expenses		4.2	1.6	0.3	4.1	1.1	0.7	1.0	+233.3	1.4	(65.9)	-	-	-	-	0.4	(90.9)	-	-
Ordinary income		57.3	90.4	12.1	14.1	18.1	20.8	16.7	+38.0	19.5	+38.3	-	-	-	-	36.2	+38.2	36.9	(5.1)
(% of Revenues)		17.5	21.1	13.9	14.8	19.3	20.1	19.5	-	20.3	-	-	-	-	-	19.9	-	17.3	-
Extraordinary gain		7.3	0.3	0.1	-	0.1	0.6	-	(100.0)	-	-	-	-	-	-	-	(100.0)	-	-
Extraordinary loss		1.4	1.3	0.0	0.0	0.0	0.0	7.1	-	0.5	-	-	-	-	-	7.6	+7,500.0	-	-
Income before income taxes etc.		63.1	89.4	12.1	14.1	18.2	21.4	9.6	(20.7)	19.0	+34.8	-	-	-	-	28.6	+9.6	-	-
(% of Revenues)		19.3	20.8	13.9	14.8	19.4	20.7	11.2	-	19.8	-	-	-	-	-	15.7	-	-	-
Net income		39.3	56.6	7.9	8.5	11.7	13.4	5.0	(36.7)	12.1	+42.4	-	-	-	-	17.1	+4.3	19.9	(20.7)
(% of Revenues)		12.0	13.2	9.1	8.9	12.5	13.0	5.8	-	12.6	-	-	-	-	-	9.4	-	9.3	-

## Statements of Revenues (YTD)

(Billions of Yen)

			FY2010				FY2011								Revised Forecast (released on July 21)			
			FY2010				FY2011								FY2011			
			1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)
			Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year(Actual)	
Sales			321.8	419.1	86.2	180.6	273.3	375.6	80.4	(6.7)	174.8	(3.2)	—	—	—	—	174.8	(3.2)
	Excl. Tamiflu		313.4	342.9	75.4	168.6	257.4	357.4	76.2	+1.1	170.2	+0.9	—	—	—	—	170.2	+0.9
	Domestic		279.9	309.3	68.0	150.6	231.3	324.4	70.2	+3.2	150.9	+0.2	—	—	—	—	150.9	+0.2
		Oncology field	102.3	123.7	28.8	64.6	100.1	141.2	31.0	+7.6	67.9	+5.1	—	—	—	—	67.9	+5.1
		Avastin	20.1	34.9	10.3	23.3	36.8	52.6	12.5	+21.4	26.4	+13.3	—	—	—	—	26.4	+13.3
		Herceptin	23.7	29.7	5.7	12.1	18.3	25.3	5.6	(1.8)	13.9	+14.9	—	—	—	—	13.9	+14.9
		Rituxan	20.5	21.1	4.5	10.3	16.1	23.0	4.9	+8.9	10.4	+1.0	—	—	—	—	10.4	+1.0
		Xeloda	4.8	6.6	2.3	5.1	7.8	10.7	2.3	+0.0	4.9	(3.9)	—	—	—	—	4.9	(3.9)
		Neutrogen	12.0	11.3	2.0	4.6	7.2	10.4	1.8	(10.0)	4.1	(10.9)	—	—	—	—	4.1	(10.9)
		Tarceva	4.5	5.8	1.4	3.5	5.5	7.9	1.7	+21.4	3.8	+8.6	—	—	—	—	3.8	+8.6
		Femara	1.7	2.4	0.6	1.4	2.2	3.2	0.8	+33.3	1.7	+21.4	—	—	—	—	1.7	+21.4
		Kytril	10.9	8.6	1.5	3.0	4.3	5.5	0.8	(46.7)	1.7	(43.3)	—	—	—	—	1.7	(43.3)
		Other products	4.1	3.3	0.6	1.3	1.9	2.5	0.5	(16.7)	1.0	(23.1)	—	—	—	—	1.0	(23.1)
		Bone and joint diseases field	50.0	57.6	13.0	28.6	44.1	62.6	14.0	+7.7	30.4	+6.3	—	—	—	—	30.4	+6.3
		Actemra	3.4	8.4	2.6	5.8	9.4	14.1	3.5	+34.6	7.6	+31.0	—	—	—	—	7.6	+31.0
		Evista	16.5	17.9	3.8	8.6	13.1	18.7	3.8	+0.0	8.4	(2.3)	—	—	—	—	8.4	(2.3)
		Suvenyl	12.0	13.7	2.9	6.4	9.7	13.6	2.6	(10.3)	6.0	(6.3)	—	—	—	—	6.0	(6.3)
		Alfarol	13.7	13.6	2.7	5.9	8.8	12.3	2.6	(3.7)	5.4	(8.5)	—	—	—	—	5.4	(8.5)
		Edirol *	—	—	—	—	—	—	—	—	0.6	—	—	—	—	—	0.6	—
		Other products	4.5	3.9	1.0	1.9	3.1	4.0	1.5	+50.0	2.4	+26.3	—	—	—	—	2.4	+26.3
		Renal diseases field	61.3	61.0	12.5	27.2	41.7	57.4	11.4	(8.8)	24.3	(10.7)	—	—	—	—	24.3	(10.7)
		Epogin	44.9	44.4	8.7	19.0	29.2	40.0	7.5	(13.8)	16.6	(12.6)	—	—	—	—	16.6	(12.6)
		Mircera	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Oxarol	10.0	10.6	2.5	5.6	8.6	12.0	2.8	+12.0	5.8	+3.6	—	—	—	—	5.8	+3.6
		Renagel	5.7	5.3	1.1	2.3	3.5	4.9	1.1	+0.0	1.7	(26.1)	—	—	—	—	1.7	(26.1)
		Other products	0.7	0.7	0.2	0.3	0.4	0.5	0.1	(50.0)	0.2	(33.3)	—	—	—	—	0.2	(33.3)
		Transplant, Immunology & Infectious diseases field	24.0	26.2	5.3	11.9	18.3	25.8	5.5	+3.8	11.5	(3.4)	—	—	—	—	11.5	(3.4)
		Pegasys	9.7	11.1	2.2	4.8	7.4	10.5	2.2	+0.0	4.4	(8.3)	—	—	—	—	4.4	(8.3)
		Copegus	4.2	4.9	0.9	2.0	3.1	4.5	0.9	+0.0	1.9	(5.0)	—	—	—	—	1.9	(5.0)
		CellCept	4.0	4.4	1.0	2.3	3.6	5.2	1.2	+20.0	2.6	+13.0	—	—	—	—	2.6	+13.0
		Rocephin	5.9	5.5	1.1	2.6	3.9	5.4	1.1	+0.0	2.4	(7.7)	—	—	—	—	2.4	(7.7)
		Other products	0.3	0.3	0.1	0.1	0.2	0.3	0.1	+0.0	0.2	+100.0	—	—	—	—	0.2	+100.0
		Others field	42.3	40.9	8.3	18.3	27.1	37.4	8.3	+0.0	16.8	(8.2)	—	—	—	—	16.8	(8.2)
		Signart	15.0	14.7	2.9	6.3	9.4	13.0	2.7	(6.9)	5.7	(9.5)	—	—	—	—	5.7	(9.5)
		Other products	27.3	26.3	5.4	12.0	17.7	24.4	5.6	+3.7	11.0	(8.3)	—	—	—	—	11.0	(8.3)
	Overseas		33.5	33.6	7.4	18.1	26.1	33.0	5.9	(20.3)	19.3	+6.6	—	—	—	—	19.3	+6.6
		Actemra	3.8	8.9	2.0	7.4	10.5	12.7	1.4	(30.0)	9.1	+23.0	—	—	—	—	9.1	+23.0
		Neutrogen	25.9	21.3	4.4	8.8	13.0	17.0	3.5	(20.5)	8.1	(8.0)	—	—	—	—	8.1	(8.0)
		Signart	2.0	1.9	0.8	1.3	1.8	2.2	0.6	(25.0)	1.2	(7.7)	—	—	—	—	1.2	(7.7)
		Other products	1.7	1.5	0.2	0.5	0.8	1.2	0.5	+150.0	0.9	+80.0	—	—	—	—	0.9	+80.0
	Tamiflu		8.4	76.2	10.8	12.0	15.8	18.2	4.2	(61.1)	4.6	(61.7)	—	—	—	—	4.6	(61.7)
		Ordinary sales	7.1	36.2	1.4	1.4	1.4	1.6	3.7	+164.3	4.1	+192.9	—	—	—	—	4.1	+192.9
		Govt. stockpile etc.	1.3	40.0	9.5	10.6	14.4	16.6	0.5	(94.7)	0.5	(95.3)	—	—	—	—	0.5	(95.3)
	Other operating revenues		5.1	9.8	0.9	1.7	2.8	3.9	5.3	+488.9	7.2	+323.5	—	—	—	—	7.2	+323.5
Revenues (total)			326.9	428.9	87.1	182.4	276.1	379.5	85.7	(1.6)	181.9	(0.3)	—	—	—	—	181.9	(0.3)
	Domestic		293.1	392.6	78.9	162.8	247.5	342.9	77.7	(1.5)	159.0	(2.3)	—	—	—	—	159.0	(2.3)
	Overseas		33.8	36.4	8.2	19.6	28.6	36.6	8.0	(2.4)	22.9	+16.8	—	—	—	—	22.9	+16.8

Note: Launched in April 2011

## Statements of Revenues (QTR)

(Billions of Yen)

			FY2010				FY2011								Revised Forecast (released on July 21)			
			FY2010				FY2011								FY2011			
			1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	7-12
			Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1st Half(Actual)	2nd Half
Sales			321.8	419.1	86.2	94.5	92.6	102.3	80.4	(6.7)	94.4	(0.1)	—	—	—	—	174.8	(3.2)
Excl. Tamiflu			313.4	342.9	75.4	93.3	88.8	100.0	76.2	+1.1	94.0	+0.8	—	—	—	—	170.2	+0.9
Domestic			279.9	309.3	68.0	82.6	80.8	93.0	70.2	+3.2	80.6	(2.4)	—	—	—	—	150.9	+0.2
Oncology field			102.3	123.7	28.8	35.7	35.5	41.1	31.0	+7.6	36.8	+3.1	—	—	—	—	67.9	+5.1
Avastin			20.1	34.9	10.3	13.0	13.5	15.8	12.5	+21.4	13.9	+6.9	—	—	—	—	26.4	+13.3
Herceptin			23.7	29.7	5.7	6.4	6.2	6.9	5.6	(1.8)	8.3	+29.7	—	—	—	—	13.9	+14.9
Rituxan			20.5	21.1	4.5	5.8	5.8	6.9	4.9	+8.9	5.5	(5.2)	—	—	—	—	10.4	+1.0
Xeloda			4.8	6.6	2.3	2.8	2.7	2.9	2.3	+0.0	2.6	(7.1)	—	—	—	—	4.9	(3.9)
Neutrogin			12.0	11.3	2.0	2.6	2.6	3.3	1.8	(10.0)	2.3	(11.5)	—	—	—	—	4.1	(10.9)
Tarceva			4.5	5.8	1.4	2.0	2.0	2.4	1.7	+21.4	2.1	+5.0	—	—	—	—	3.8	+8.6
Femara			1.7	2.4	0.6	0.8	0.8	1.0	0.8	+33.3	0.9	+12.5	—	—	—	—	1.7	+21.4
Kytril			10.9	8.6	1.5	1.5	1.3	1.2	0.8	(46.7)	0.9	(40.0)	—	—	—	—	1.7	(43.3)
Other products			4.1	3.3	0.6	0.7	0.6	0.7	0.5	(16.7)	0.5	(28.6)	—	—	—	—	1.0	(23.1)
Bone and joint diseases field			50.0	57.6	13.0	15.7	15.4	18.5	14.0	+7.7	16.4	+4.5	—	—	—	—	30.4	+6.3
Actemra			3.4	8.4	2.6	3.3	3.6	4.7	3.5	+34.6	4.1	+24.2	—	—	—	—	7.6	+31.0
Evista			16.5	17.9	3.8	4.8	4.5	5.6	3.8	+0.0	4.6	(4.2)	—	—	—	—	8.4	(2.3)
Suvenyl			12.0	13.7	2.9	3.5	3.3	3.9	2.6	(10.3)	3.4	(2.9)	—	—	—	—	6.0	(6.3)
Alfarol			13.7	13.6	2.7	3.2	2.9	3.5	2.6	(3.7)	2.8	(12.5)	—	—	—	—	5.4	(8.5)
Edirol			—	—	—	—	—	—	—	—	0.6	—	—	—	—	—	0.6	—
Other products			4.5	3.9	1.0	0.9	1.1	0.9	1.5	+50.0	0.9	+0.0	—	—	—	—	2.4	+26.3
Renal diseases field			61.3	61.0	12.5	14.7	14.6	15.6	11.4	(8.8)	12.9	(12.2)	—	—	—	—	24.3	(10.7)
Epogin			44.9	44.4	8.7	10.3	10.2	10.8	7.5	(13.8)	9.1	(11.7)	—	—	—	—	16.6	(12.6)
Mircera			—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	12.4
Oxarol			10.0	10.6	2.5	3.1	3.0	3.4	2.8	+12.0	3.0	(3.2)	—	—	—	—	5.8	+3.6
Renagel			5.7	5.3	1.1	1.2	1.2	1.3	1.1	+0.0	0.7	(41.7)	—	—	—	—	1.7	(26.1)
Other products			0.7	0.7	0.2	0.1	0.1	0.1	0.1	(50.0)	0.1	+0.0	—	—	—	—	0.2	(33.3)
Transplant, Immunology & Infectious diseases field			24.0	26.2	5.3	6.6	6.4	7.4	5.5	+3.8	6.0	(9.1)	—	—	—	—	11.5	(3.4)
Pegasys			9.7	11.1	2.2	2.6	2.6	3.0	2.2	+0.0	2.3	(11.5)	—	—	—	—	4.4	(8.3)
Copegus			4.2	4.9	0.9	1.1	1.1	1.3	0.9	+0.0	1.0	(9.1)	—	—	—	—	1.9	(5.0)
CellCept			4.0	4.4	1.0	1.3	1.3	1.5	1.2	+20.0	1.4	+7.7	—	—	—	—	2.6	+13.0
Rocephin			5.9	5.5	1.1	1.5	1.4	1.5	1.1	+0.0	1.3	(13.3)	—	—	—	—	2.4	(7.7)
Other products			0.3	0.3	0.1	0.1	0.1	0.1	0.1	+0.0	0.1	+0.0	—	—	—	—	0.2	+100.0
Others field			42.3	40.9	8.3	9.9	8.8	10.3	8.3	+0.0	8.4	(15.2)	—	—	—	—	16.8	(8.2)
Sigmart			15.0	14.7	2.9	3.4	3.0	3.7	2.7	(6.9)	3.0	(11.8)	—	—	—	—	5.7	(9.5)
Other products			27.3	26.3	5.4	6.5	5.8	6.7	5.6	+3.7	5.4	(16.9)	—	—	—	—	11.0	(8.3)
Overseas			33.5	33.6	7.4	10.7	8.0	6.9	5.9	(20.3)	13.4	+25.2	—	—	—	—	19.3	+6.6
Actemra			3.8	8.9	2.0	5.4	3.1	2.2	1.4	(30.0)	7.7	+42.6	—	—	—	—	9.1	+23.0
Neutrogin			25.9	21.3	4.4	4.4	4.2	4.0	3.5	(20.5)	4.6	+4.5	—	—	—	—	8.1	(8.0)
Sigmart			2.0	1.9	0.8	0.6	0.4	0.4	0.6	(25.0)	0.6	+0.0	—	—	—	—	1.2	(7.7)
Other products			1.7	1.5	0.2	0.3	0.3	0.3	0.5	+150.0	0.4	+33.3	—	—	—	—	0.9	+80.0
Tamiflu			8.4	76.2	10.8	1.2	3.8	2.3	4.2	(61.1)	0.4	(66.7)	—	—	—	—	4.6	(61.7)
Ordinary sales			7.1	36.2	1.4	0.0	0.0	0.2	3.7	+164.3	0.4	—	—	—	—	—	4.1	+192.9
Govt. stockpile etc.			1.3	40.0	9.5	1.2	3.8	2.1	0.5	(94.7)	—	(100.0)	—	—	—	—	0.5	(95.3)
Other operating revenues			5.1	9.8	0.9	0.8	1.1	1.1	5.3	+488.9	1.8	+125.0	—	—	—	—	7.2	+323.5
Revenues (total)			326.9	428.9	87.1	95.3	93.7	103.4	85.7	(1.6)	96.2	+0.9	—	—	—	—	181.9	(0.3)
Domestic			293.1	392.6	78.9	83.9	84.7	95.5	77.7	(1.5)	81.3	(3.1)	—	—	—	—	159.0	(2.3)
Overseas			33.8	36.4	8.2	11.4	9.0	8.0	8.0	(2.4)	14.9	+30.7	—	—	—	—	22.9	+16.8

## Balance Sheets

(Billions of Yen)

	FY2008	FY2009	FY2010				FY2011					
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	vs. Jun. 30, 2010	vs. Dec. 31, 2010	As of Sep. 30	As of Dec. 31
Cash and deposits	70.8	107.0	101.1	81.3	70.2	76.2	101.7	109.2	+27.9	+33.0	–	–
Trade notes and accounts receivable	108.5	121.6	85.4	99.2	99.3	113.4	94.6	105.8	+6.6	(7.6)	–	–
Marketable securities	54.7	52.2	55.7	61.7	58.7	59.7	58.0	59.0	(2.7)	(0.7)	–	–
Inventories	78.7	92.6	100.0	111.7	115.9	104.9	108.5	110.4	(1.3)	+5.5	–	–
Other current assets	31.7	37.9	41.7	29.5	35.0	32.3	39.7	27.6	(1.9)	(4.7)	–	–
Total Current assets	344.4	411.3	383.9	383.4	379.1	386.5	402.5	412.1	+28.7	+25.6	–	–
Property, plant and equipment	98.3	93.7	91.4	89.8	88.4	88.0	86.1	83.5	(6.3)	(4.5)	–	–
Intangible assets	3.1	3.2	3.0	2.6	2.6	2.4	2.3	2.4	(0.2)	+0.0	–	–
Investments and other assets	32.7	32.3	32.9	31.4	31.1	31.2	29.3	31.3	(0.1)	+0.1	–	–
thereof Investment securities	14.4	9.7	9.5	8.0	7.3	7.6	7.0	6.9	(1.1)	(0.7)	–	–
Total Noncurrent Assets	134.2	129.2	127.2	123.8	122.1	121.5	117.8	117.3	(6.5)	(4.2)	–	–
Total Assets	478.5	540.5	511.1	507.2	501.2	508.0	520.3	529.4	+22.2	+21.4	–	–
Trade notes and accounts payable	28.8	34.3	35.4	32.2	26.2	19.5	29.5	28.5	(3.7)	+9.0	–	–
Short-term loans and bonds	–	–	–	–	–	–	–	–	–	–	–	–
Other current liabilities	49.8	66.2	42.2	36.3	33.2	35.1	42.4	40.3	+4.0	+5.2	–	–
Total current liabilities	78.5	100.5	77.6	68.5	59.4	54.6	72.0	68.8	+0.3	+14.2	–	–
Long-term debt and bonds	–	–	–	–	–	–	–	–	–	–	–	–
Other noncurrent liabilities	2.9	5.4	5.2	4.8	5.0	4.0	5.3	5.3	+0.5	+1.3	–	–
Total noncurrent liabilities	2.9	5.4	5.2	4.8	5.0	4.0	5.3	5.3	+0.5	+1.3	–	–
Total liabilities	81.5	105.9	82.8	73.3	64.4	58.6	77.3	74.1	+0.8	+15.5	–	–
Common stock	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	–	–	–	–
Additional paid-in capital	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	–	–	–	–
Retained earnings	271.0	308.0	303.3	311.8	314.3	327.6	320.1	332.2	+20.4	+4.6	–	–
Treasury stock, at cost	(35.2)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	+0.0	+0.0	–	–
Net unrealized gain on securities	1.4	1.6	1.8	1.5	1.2	1.3	1.0	0.9	(0.6)	(0.4)	–	–
Foreign currency translation adjustments	(7.9)	(6.8)	(8.2)	(11.1)	(10.1)	(11.3)	(9.5)	(9.7)	+1.4	+1.6	–	–
New share warrants	0.3	0.5	0.6	0.6	0.7	0.8	0.8	0.9	+0.3	+0.1	–	–
Minority interests	1.7	1.8	1.3	1.4	1.2	1.4	1.0	1.4	+0.0	+0.0	–	–
Total net assets	397.1	434.7	428.4	433.9	436.7	449.4	443.0	455.3	+21.4	+5.9	–	–
Total liabilities and net assets	478.5	540.5	511.1	507.2	501.2	508.0	520.3	529.4	+22.2	+21.4	–	–

## Cash Flows

(Billions of Yen)

	FY2008	FY2009	FY2010				FY2011			
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
Net cash provided by (used in) operating activities	39.3	66.5	16.4	6.8	4.4	15.6	39.6	50.2	—	—
Net cash provided by (used in) investing activities	(14.1)	(20.3)	1.2	(16.6)	(16.2)	(20.2)	(0.8)	(3.7)	—	—
Net cash provided by (used in) financing activities	(18.4)	(22.3)	(13.2)	(13.2)	(23.1)	(23.1)	(13.2)	(13.2)	—	—
Effect of exchange rate changes on cash and cash equivalents	(9.9)	(0.1)	(0.6)	(1.5)	(1.2)	(1.7)	0.7	0.6	—	—
Net increase (decrease) in cash and cash equivalents	(3.1)	23.8	3.8	(24.5)	(36.1)	(29.3)	26.4	34.0	—	—
Cash and cash equivalents at beginning of period	73.7	70.7	94.5	94.5	94.5	94.5	65.1	65.1	—	—
Cash and cash equivalents at end of period	70.7	94.5	98.2	69.9	58.4	65.1	91.6	99.1	—	—

## Performance Indicators

	FY2008	FY2009	FY2010				FY2011				Revised Forecast (released on July 21)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Net income per share (Basic)	72.07yen	104.00yen	14.43yen	30.09yen	51.55yen	76.14yen	9.17yen	31.40yen	—	—	67.99yen
Net income per share (Fully diluted)	72.04yen	103.98yen	14.43yen	30.09yen	51.54yen	76.12yen	9.17yen	31.39yen	—	—	—
Ratio of net income to shareholders' equity *	10.1%	13.7%	1.8%	3.8%	6.5%	9.4%	1.1%	3.8%	—	—	—
Ratio of ordinary income to total assets *	12.2%	17.7%	2.3%	5.0%	8.5%	12.4%	3.2%	7.0%	—	—	—
Net assets per share	725.18yen	794.51yen	783.67yen	793.50yen	799.11yen	821.87yen	810.62yen	832.45yen	—	—	—
Equity ratio	82.6%	80.0%	83.4%	85.1%	86.8%	88.0%	84.8%	85.6%	—	—	—
Dividend per share (Annual)	34yen	40yen				40yen					40yen
Dividend per share (Interim)	15yen	17yen				17yen				20yen	20yen
Dividend payout ratio (Consolidated)	47.2%	38.5%				52.5%				—	58.8%

Note: Quarterly (year-to-date) Ratio of net income to shareholders' equity and Ratio of ordinary income to total assets are not annualized.

## Number of Employees

	FY2008	FY2009	FY2010				FY2011				Revised Forecast (released on July 21)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Number of employees	6,383	6,485	6,472	6,707	6,723	6,709	6,635	6,818	—	—	6,830

Note: Number of employees doesn't include staff seconded to companies outside the Group.

## Capital Expenditures

(Billions of Yen)

	FY2008	FY2009	FY2010				FY2011				Revised Forecast (released on July 21)
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
Capital expenditures	26.6	14.6	1.8	4.6	7.9	12.7	1.4	4.6	—	—	13.0
Depreciation	19.4	19.5	4.1	8.4	13.0	18.0	3.8	7.2	—	—	16.0



## Development pipeline (as of July 21, 2011)

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<b><u>Oncology</u></b>					
RG340	Gastric cancer #	Approved Feb. 11	capecitabine Xeloda Oral	Roche Xeloda	Antimetabolite, 5-FU derivative
RG597	Gastric cancer #	Approved Mar. 11	trastuzumab Herceptin Injection	Roche Herceptin	Anti-HER2 humanized monoclonal antibody
RG1415	Pancreatic cancer #	Approved Jul. 11	erlotinib HCl Tarceva	Roche/OSI Tarceva	EGFR tyrosine kinase inhibitor
	Non-small cell lung cancer (1st line) #	Phase II	Oral		
RG435	Breast cancer #	Filed Oct. 09	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF(Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Gastric cancer #	Phase III Multinational study			
	Breast cancer (adjuvant) #	Phase III Multinational study			
	Glioblastoma #	Phase III Multinational study			
	Glioblastoma (relapsed) #	Phase II			
EPOCH	Chemotherapy-induced anemia #	Filed Nov. 09	epoetin beta Epogin Injection	In-house	Recombinant human erythropoietin
RG1273	Breast cancer	Phase III Multinational study	pertuzumab Injection	Roche	Humanized HER dimerization inhibitory monoclonal antibody
RG3502	Breast cancer	Phase III Multinational study	Injection	Roche	HER2 antibody-drug conjugate (T-DM1)
MRA	Pancreatic cancer #	Phase I / II	tocilizumab Actemra Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
AF802	Non-small cell lung cancer	Phase I / II	Oral	In-house	ALK inhibitor
WT4869	Myelodysplastic syndromes	Phase I / II	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
CIF (RG7167)	Solid tumors	Phase I	Oral	In-house	MEK inhibitor
		Phase I Overseas		(Roche)	
CKI27 (RG7304)	Solid tumors	Phase I	Oral	In-house	Raf and MEK dual inhibitor
		Phase I Overseas		(Roche)	
GC33	Liver cancer	Phase I	Injection	In-house	Humanized anti-Glypican-3 monoclonal antibody
		Phase I Overseas		(Roche)	
PA799	Solid tumors	Phase I Overseas	Oral	In-house	-
GA101 (RG7159)	Non-Hodgkin's lymphoma	Phase I	Injection	Roche	Humanized anti-CD20 monoclonal antibody
TP300	Gastric cancer, etc	Development suspended	Injection	In-house	Topoisomerase I inhibitor
<b><u>Bone and Joint diseases</u></b>					
ED-71	Osteoporosis	Launched Apr. 11	eldecalcitol Edirol Oral	In-house (Taisho Pharmaceutical)	Active Vitamin D <sub>3</sub> derivative

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
MRA	Systemic-onset juvenile idiopathic arthritis (sJIA) #	Approved Apr. 11 US	tocilizumab Actemra / RoActemra(EU) Injection	In-house  (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
		Filed Oct. 10 EU			
	Rheumatoid arthritis (new formulation: subcutaneous injection)	Phase III			
		Phase III Overseas			
RG484	Osteoporosis	Phase II / III	ibandronate sodium hydrate Injection	Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical)	Bisphosphonate
		Phase II	ibandronate sodium hydrate Oral		
SA237	Rheumatoid arthritis	Phase I	Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody
<b><u>Renal diseases</u></b>					
RG744	Renal anemia	Launched Jul. 11	Epoetin beta pegol Mircera Injection	Roche Mircera	Continuous erythropoietin receptor activator
<b><u>Transplant, Immunology and Infectious diseases</u></b>					
RG964	Compensated liver cirrhosis caused by hepatitis C virus	Approved Jul. 11	ribavirin Copegus Oral	Roche Copegus	Anti-viral agent, in combination with Pegasys
RG442	# Chronic hepatitis B #		peginterferon alfa-2a Pegasys Injection	Roche Pegasys	Peginterferon alfa-2a agent (recombinant)
RG7128	Chronic hepatitis C	Phase I	mericitabine	Roche	Polymerase inhibitor
<b><u>Other diseases</u></b>					
CSG452	Type II diabetes	Phase III	tofogliflozin  Oral	In-house	SGLT2 inhibitor

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG1678	Schizophrenia	Phase III Multinational study	Oral	Roche	Glycine reuptake inhibitor
RG1450	Alzheimer's disease	Phase I	gantenerumab Injection	Roche/Morphosys	Human anti-amyloid-beta monoclonal antibody
RG7090	Major depressive disorder	Phase I	Oral	Roche	mGluR5 antagonist

Changes from the last announcement on April 21, 2011

Oncology

-RG1415 (Tarceva)  
-RG3502  
-TP300

Filed → Approved (Pancreatic cancer)  
Phase II → Phase III Multinational study (Breast cancer)  
Phase II → Development suspended (Gastric cancer, etc)

Renal diseases

-RG744 (Mircera)

Filed → Launched (Renal anemia)

Transplant, Immunology and Infectious diseases

-RG964/RG442 (Pegasys/Copegus)  
-RG7128

Filed → Approved (Compensated liver cirrhosis caused by hepatitis C virus)  
Phase I (Chronic hepatitis C: Starting development)

Other diseases

-RG7090

Phase I (Major depressive disorder: Starting development)

## R&amp;D Activities (Jan. 1, 2011 – Jul. 21, 2011)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- In February, we obtained an approval for an additional indication of a 5-FU derivative, RG340 (product name: Xeloda) for advanced or recurrent gastric cancer, which is not amenable to curative resection.
- In March, we obtained an approval for an additional indication of a humanized anti-HER2 monoclonal antibody, RG597 (product name: Herceptin) for advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection.
- In July, we obtained an approval for an additional indication of an EGFR tyrosine kinase inhibitor, RG1415 (product name: Tarceva) for pancreatic cancer.
- In May, we joined a Phase III multinational study (expected indication: Breast cancer) for a HER2 antibody-drug conjugate (T-DM1), RG3502.

Bone and Joint diseases

- In April, we launched an active Vitamin D3 derivative, ED-71 (product name: Ediol), for osteoporosis.

Renal diseases

- In July, we launched a continuous erythropoietin receptor activator, RG744 (product name: Mircera), for renal anemia.

Transplant, Immunology and Infectious Diseases

- In July, we obtained an approval for an additional indication of an anti-viral agent, RG964 (Product name: Copegus), in combination with a peginterferon alfa-2a agent (recombinant), RG442 (product name: Pegasys), for compensated liver cirrhosis caused by hepatitis C virus.
- In January, we filed an application for an expected indication of a peginterferon alfa-2a agent (recombinant), RG442 (product name: Pegasys), for chronic hepatitis B.

Other Diseases

- We decided to suspend our development for a GLP-1 analogue, RG1583 (expected indication: Type II diabetes), following the fact that Roche returned the development license of the compound to Ipsen.
- In January, we joined a Phase III multinational study (expected indication: Schizophrenia) for a Glycine reuptake inhibitor, RG1678.
- In June, we started a Phase I study (expected indication: Major depressive disorder) for an mGluR5 antagonist, RG7090.

At present, we are awaiting the approvals of applications (new molecular entities or additions of indications) filed for 4 development themes, including RG435 (product name: Avastin, expected indication: breast cancer).

Also, as for development activities overseas, the Company saw progress as described below.

- We decided to suspend our development for a topoisomerase I inhibitor, TP300 (expected indication: Gastric cancer, etc.), following the fact that the results did not meet the efficacy criteria to proceed.
- In April, Roche obtained an approval for an additional indication of a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra), for Systemic-onset juvenile idiopathic arthritis (sJIA) in US.

**Major clinical trials in oncology field currently running in Japan**

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG435 (bevacizumab) Avastin	Breast cancer	paclitaxel + RG435	Filed (Oct. 09)	-
	Breast cancer (adjuvant)	standard chemotherapy ± RG435	BEATRICE study : Phase III Multinational study	2014   2016
	Glioblastoma	temozolomide ± RG435	Phase III Multinational study	2014   2016
	Glioblastoma [relapsed]	RG435	Phase II	2014   2016
RG1415 (erlotinib HCl) Tarceva	Pancreatic cancer	gemcitabine + RG1415	Approved (Jul. 11)	-
	Non-small cell lung cancer(1st line)	RG1415	Phase II	2012
RG1273 (pertuzumab)	Breast cancer	RG597 + docetaxel ± RG1273	CLEOPATRA study : Phase III Multinational study	2012
RG3502 (T-DM1)	Breast cancer	RG3502	MARIANNE study : Phase III Multinational study	2013